Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib

• Published in: Clinical genitourinary cancer Vol. 11; no. 2; pp. 107 - 114
• Main Authors: Rini, Brian I, de La Motte Rouge, Thibault, Harzstark, Andrea L, Michaelson, M. Dror, Liu, Glenn, Grünwald, Viktor, Ingrosso, Antonella, Tortorici, Michael A, Bycott, Paul, Kim, Sinil, Bloom, Joanna, Motzer, Robert J
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2013
• Subjects: Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Female; Hematology, Oncology and Palliative Medicine; Humans; Imidazoles - adverse effects; Imidazoles - therapeutic use; Indazoles - adverse effects; Indazoles - therapeutic use; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Long-term survival; Male; Middle Aged; Pharmacokinetics; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Survival Rate; Treatment Outcome; Tyrosine kinase inhibitor; Urology; Vascular endothelial growth factor receptor inhibitor; Long-term survival; Pharmacokinetics; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor inhibitor
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2012.12.004

Micro-Abstract This report presents an update of overall survival data retrospectively collected from a phase II study of axitinib in patients with cytokine-refractory metastatic renal cell carcinoma. The 5-year overall survival rate was 20.6%. A post hoc analysis showed improved clinical outcomes in patients with peak post–first-dose axitinib plasma concentrations within a specific range.